Two weeks ago, I gave a presentation to the Florida Chapter of the American Association of Consultant Pharmacists. The focus of the presentation was on the team concept for diabetes management and all the different professionals that play a role. One part of the presentation was about the new insulins …

In part 2 of this Exclusive Interview, DIC Publisher Steve Freed asks about the success of anti-VEGF agents with lower A1Cs.

In this week's Homerun Slides, prioritizing patient characteristics to determine best type 2 treatment agent.

Transport of proinsulin from the ER to Golgi apparatus: After proinsulin is translocated into the lumen of the ER, it is then delivered in transport “COP-coated vesicles” to the cis-Golgi apparatus. Up until relatively recently, it was thought that newly synthesized proinsulin was passed from the cis-Golgi network “stack” via the medial- to the trans-stack of the Golgi apparatus stacks in “COP”-coated vesicles,